FDA Grants Priority Review to Sonesitatug Vedotin for Advanced Gastric Cancer

FDA Grants Priority Review to Sonesitatug Vedotin for Advanced Gastric Cancer

The US Food and Drug Administration (FDA) has accepted AstraZeneca’s Biologics License Application (BLA) for sonesitatug vedotin (Sone-Ve) and granted Priority Review for patients with previously treated, Claudin 18.2 (CLDN18.2)-positive advanced gastric and gastroesophageal cancers.

The regulatory decision follows results from the Phase III CLARITY-Gastric01 trial, in which the investigational antibody-drug conjugate (ADC) reduced the risk of death by 42% compared with investigator’s choice of therapy in the second-line and later treatment setting.

The FDA is expected to make its regulatory decision in the second quarter of 2027, potentially introducing a new biomarker-directed treatment option for patients whose disease has progressed after initial therapy.

A New Targeted Option for Previously Treated Gastric Cancer

Despite advances in systemic treatment, outcomes remain poor for patients with advanced gastric and gastroesophageal junction (GEJ) cancers, particularly after disease progression on first-line therapy.

Approximately 7,500 patients in the United States receive second-line or later treatment annually for advanced or metastatic CLDN18.2-positive, HER2-negative gastric or GEJ cancers.

CLDN18.2, a protein normally found in the stomach lining, has become an important therapeutic target in gastrointestinal oncology. Approximately 60% of gastric and GEJ cancers express CLDN18.2 in at least 25% of tumor cells, according to estimates cited by AstraZeneca.

The proposed indication for sonesitatug vedotin includes patients with locally advanced or metastatic gastric cancer, GEJ cancer, or esophageal adenocarcinoma whose tumors express CLDN18.2 in at least 25% of cells, regardless of staining intensity.

This relatively broad biomarker threshold distinguishes the investigational treatment from existing CLDN18.2-directed approaches that require higher levels of target expression.

CLARITY-Gastric01 Demonstrates an Overall Survival Benefit

The FDA application is supported by findings from CLARITY-Gastric01, a global, randomized, Phase III trial conducted across 175 centers in 19 countries.

The study evaluated sonesitatug vedotin against investigator’s choice of treatment in patients with advanced or metastatic gastric cancer, GEJ cancer, or esophageal adenocarcinoma who had received at least one prior line of systemic therapy.

Results presented at the European Society for Medical Oncology (ESMO) Congress 2026 demonstrated an improvement in overall survival.

In the second-line and later population:

  • Median overall survival: 10.6 months with sonesitatug vedotin versus 6.4 months with investigator’s choice.
  • Risk of death: Reduced by 42% (HR 0.58; 95% CI 0.47–0.73; p=0.000004).
  • 12-month overall survival: 42.6% versus 27.8%, respectively.

The survival benefit was also observed in the third-line and later population, where sonesitatug vedotin met one of the trial’s dual primary endpoints.

In this population, median overall survival was 10.0 months versus 5.0 months, representing a 53% reduction in the risk of death (HR 0.47; 95% CI 0.36–0.62; p<0.000001).

However, the trial’s other dual primary endpoint, progression-free survival assessed by blinded independent central review in the overall second-line and later population, did not meet statistical significance. Median progression-free survival was 4.2 months versus 3.8 months (HR 0.77; p=0.053193).

These findings establish an important distinction between the demonstrated overall survival advantage and the less conclusive progression-free survival results.

FDA Grants Priority Review to Sonesitatug Vedotin for Advanced Gastric Cancer

Why CLDN18.2 Expression Levels Matter

An important aspect of CLARITY-Gastric01 is its inclusion of patients across a wider range of CLDN18.2 expression levels.

Exploratory subgroup analyses showed overall survival hazard ratios favoring sonesitatug vedotin in patients with both higher expression (at least 75% of tumor cells) and lower expression (25% to less than 75%).

This suggests that the potential therapeutic population may extend beyond patients with strongly CLDN18.2-expressing tumors.

However, the subgroup findings are exploratory, and the benefit observed in the overall study population should not be assumed to apply equally to every clinical subgroup.

If approved, the treatment could expand the role of CLDN18.2 testing in determining subsequent treatment options for advanced gastric and gastroesophageal cancers.

Safety and Tolerability of Sonesitatug Vedotin

AstraZeneca reported that sonesitatug vedotin demonstrated a safety profile consistent with previous clinical experience, without new safety signals.

Data from CLARITY-Gastric01 showed differences in adverse-event patterns between the investigational ADC and the comparator treatments.

Gastrointestinal adverse events, including nausea, vomiting and decreased appetite, were more frequent among patients receiving sonesitatug vedotin. Conversely, Grade 3 or higher neutropenia was less frequent with the ADC than with investigator’s choice of treatment.

These findings highlight the importance of appropriate supportive care and adverse-event management when evaluating the potential role of sonesitatug vedotin in routine clinical practice.

AstraZeneca Highlights the Potential for a New Treatment Approach

Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca, emphasized the unmet need for patients whose cancer progresses after first-line treatment.

The company noted that sonesitatug vedotin is the first CLDN18.2-directed ADC to demonstrate an overall survival advantage over investigator-selected therapy in this previously treated setting.

Sonesitatug vedotin is designed to deliver a cytotoxic payload, monomethyl auristatin E (MMAE), through an antibody that recognizes CLDN18.2-expressing cells. This approach differs from conventional chemotherapy through its biomarker-directed drug delivery.

The agent has also received Orphan Drug Designation from the FDA and European Commission for gastric and GEJ cancers, while regulatory applications are under review in the European Union, China and several other countries.

What Comes Next for Sonesitatug Vedotin?

Beyond the current regulatory submission, AstraZeneca is investigating sonesitatug vedotin in earlier treatment settings and additional gastrointestinal malignancies.

The Phase III CLARITY-Gastric02 trial is evaluating the ADC in combination with capecitabine, with or without rilvegostomig, as first-line treatment for advanced gastric cancer, GEJ cancer and esophageal adenocarcinoma.

Additional Phase II studies are exploring combinations in advanced solid tumors, including CLDN18.2-positive pancreatic and biliary tract cancers.

For now, the immediate regulatory milestone is the FDA’s anticipated decision in the second quarter of 2027.

Priority Review does not constitute FDA approval, and sonesitatug vedotin remains investigational in the United States. Nevertheless, the overall survival findings from CLARITY-Gastric01 provide the basis for evaluating a potential new targeted treatment option for patients with previously treated CLDN18.2-positive advanced gastric and gastroesophageal cancers.

Read further on OncoDaily: The AstraZeneca Foundation Awards Over $1.1 Million to Expand Community Healthcare Access

FDA Grants Priority Review to Sonesitatug Vedotin for Advanced Gastric Cancer

Nare Hovhannisyan
Fact checked by Nare Hovhannisyan MD, Medical Writer
Eliz Baloyan
Medically reviewed by Eliz Baloyan MD, Features Writer and Editor at OncoDaily and CancerWorld